Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM-Reference-Cited by-同舟云学术

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Published:2017-11-30 Issue:22 Volume:130 Page:2392-2400
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Moreau Philippe¹,Chanan-Khan Asher²,Roberts Andrew W.³⁴,Agarwal Amit B.⁵,Facon Thierry⁶,Kumar Shaji⁷,Touzeau Cyrille¹,Punnoose Elizabeth A.⁸,Cordero Jaclyn⁹,Munasinghe Wijith⁹,Jia Jia⁹,Salem Ahmed Hamed⁹¹⁰,Freise Kevin J.⁹,Leverson Joel D.⁹,Enschede Sari Heitner⁹,Ross Jeremy A.⁹,Maciag Paulo C.⁹,Verdugo Maria⁹,Harrison Simon J.¹¹¹²

Affiliation:

1. Centre Hospitalier Universitaire de Nantes, University Hospital Hôtel-Dieu, Nantes, France;

2. Mayo Clinic, Jacksonville, FL;

3. Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia;

4. Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia;

5. The University of Arizona Cancer Center, Tucson, AZ;

6. Centre Hospitalier Regional Universitaire Lille, Hôpital Claude Huriez, Lille, France;

7. Mayo Clinic, Rochester, MN;

8. Genentech Inc., South San Francisco, CA;

9. AbbVie Inc., North Chicago, IL;

10. Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt;

11. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; and

12. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

Abstract

Key Points In relapsed/refractory MM, venetoclax plus bortezomib and dexamethasone appears to be safe and efficacious. This is a novel therapeutic approach for MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/22/2392/1403811/blood788323.pdf

Reference34 articles.

1. Frontline therapy of multiple myeloma;Moreau;Blood,2015

2. Novel agents in the treatment of multiple myeloma: a review about the future;Naymagon;J Hematol Oncol,2016

3. Reprogramming cell death: BCL2 family inhibition in hematological malignancies;Scarfò;Immunol Lett,2013

4. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies;Delbridge;Nat Rev Cancer,2016

5. Apoptosis therapy: driving cancers down the road to ruin;Green;Nat Med,2013

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

3. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

4. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

5. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07